维普期刊资源整合服务平台（V6.5）

26篇 您的检索式：作者名="Boyer MJ"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Regulation of intracellular pH in tumor cell lines: influence of microenvironmental conditions显示文摘	Tannock IF	1992	Cancer Res1992，52，16：	1
2	A phase Ⅰ/Ⅱ study of pemetrexed and vinorelbine in patients with non-small cell lung cancer 显示文摘	Clarke SJ Boyer MJ Millward M	2005	Lung Cancer2005，49，3：	1
3	Human arteries engineered in vitro显示文摘	McKee JA Banik SS Boyer MJ		0，，06：	1
4	Lipid-modified surface protein antigens expressing size variation within the species Mycoplasma hyorhinis 显示文摘	Boyer MJ Wise KS	1989	Infect Immun1989，57，1：	1
5	Focal and segmental glomerulosclerosis in children : A longitudinal assessment显示文摘	Boyer O Moulder JK Somers MJ	2007	Pediatr Nephrot2007，22，8：	1
6	(3,3-Diflu- oro-pyrrolidin-1 -yl ) --methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor显示文摘	Arnmirati MJ Andrews KM BOYER DD etal	2009	Bioorg Med Chem Lett2009，19，7：	1
7	Docetaxel and carboplatin is an active regimenin advanced ono- small- cell lung cancer: a phase Ⅱ study in Caucasian and Asian patients显示文摘	Millward MJ Boyer MJ Lehnert M	2003	Ann Oncol2003，14，6：	1
8	Human arteries engineered in vitro显示文摘	McKee JA Banik SS Boyer MJ	2003	EMBO Rep2003，4，：	1
9	(3,3-Di- fluoropyrrolidin- 1-yl) - ( ( 2 S, 4S) -4- (4- (pyrimidin-2-yl) piperazin-l-yl) pyrrolidin-2-yl)-methanone: a potent, se- lective, orally active dipeptidyl peptidase IV inhibitor显示文摘	Ammirati MJ Andrews KM Boyer DD	2009	Bioorg Med Chem Lett2009，19，7：	1
10	Efficacy and safety of PF299804 versus erlotinib (E): a global, randomize phase II trial in patients with advanced non small cell-lung cancer ( NSCLC) after failure of chemotherapy (CT)显示文摘	Boyer MJ Blackball FH Park K	2010	Proc Am Soc Clin Oncol2010，28，8：	1
11	Efficacy and safety of P versus erlotinib: a global randomized phase 2 trial in patients with advanced non-small cell lung cancer after failure of chemotherapy显示文摘	Boyer MJ Blackhall FH Park K	2010	J Clin Oncol2010，，：	1
12	Human arteries engineered in vitro显示文摘	McKee JA Banik SS Boyer MJ		0，，06：	1
13	Human arteries engineered in vitro显示文摘	McKee JA Banik SS Boyer MJ	2003	EMBO Rep2003，4，：	1
14	Recent progress in flexor tendon healing显示文摘	Sliva MJ Boyer MI Gelberman RH	2002	J Orthop Sci2002，7，4：	1
15	Human arteries engineered in vitro显示文摘	McKee JA Banik SS Boyer MJ	2003	EMBO Rep2003，4，6：	1
16	Human arteries engineered in vitro显示文摘	McKee JA Banik SS Boyer MJ Hamad NM Lawson JH Niklason LE	2003	EMBO Rep2003，4，：	1
17	Dacomitinib (D; PF-00299804 )versus erlotinib ( E) for advanced ( adv) non-smallcell lung cancer ( NSCLC) -A randomized double-blind phase IIIstudy 显示文摘	BOYER MJ JANNE PA MOK T		/ Clin Oncol0，，：	1
18	Docetaxel and carboplatinis an active regimen in advanced non-small-cell lung cancer:a phaseII study in Caucasian and Asian patients 显示文摘	Millward MJ Boyer MJ Lehnert M	2003	Ann Oncol2003，14，3：	1
19	A phase Ⅰ/Ⅱ study of pemetrexed and vinorelbine in patients with non-small cell lung cancer显示文摘	Clarke SJ Boyer MJ Millward M	2005	Lung Cancer2005，49，3：	1
20	A phase Ⅰ/Ⅱ study of pemetrexed and vinorelbine in patients with nonsmall cell lung cancer显示文摘	Clarke SJ Boyer MJ Millward M	2005	Lung Cancer2005，49，3：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示